Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin
- 6 May 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 378 (1), 73-83
- https://doi.org/10.1007/s00210-008-0289-4
Abstract
The antidepressant mianserin exhibits a tetracyclic structure that is different from typical tricyclic antidepressants (TCA) and that of selective serotonin reuptake inhibitors. In comparison to the older TCA, mianserin has been shown to have a superior risk profile regarding proarrhythmic effects, both in vitro and in vivo. However, the underlying molecular electrophysiological basis has not been elucidated to date. Therefore, we studied the effects of mianserin on cardiac hERG potassium channels, the predominant target of drug-induced proarrhythmia. HERG channels were expressed in the Xenopus oocyte expression system and in human embryonic kidney (HEK) cells and currents were measured with two-microelectrode voltage-clamp and whole-cell patch-clamp, respectively. Mianserin inhibited hERG currents in a dose-dependent manner with an IC50 of 3.2 μmol/l in HEK cells. Onset of blockade was slow and the inhibitory effect was not reversible upon wash-out of the drug. In hERG channel mutants, Y652A and F656A, lacking aromatic residues in the S6 domain, the effect of mianserin was significantly reduced in comparison to the wild type. Mianserin inhibited hERG currents in the open and inactivated state, but not in the closed states. HERG inactivation kinetics were significantly altered by mianserin without marked effects on channel activation kinetics. The inhibitory effect was not frequency dependent. In conclusion, mianserin is a low-affinity hERG-blocking agent. However, taken together with the lack of APD-prolongation shown in other studies, mianserin seems to have a good safety profile. Lack of consistent QT prolonging effects of mianserin in previous studies may therefore be linked to additional effects such as inhibition of other cardiac ion channels. However, as demonstrated by clinical case reports, mianserin can induce proarrhythmic effects in susceptible patients. Therefore, in patients with complex co-medication (i.e., additional hERG-blocking agents) and in patients with risk factors for acquired long QT syndrome as well as in cases of overdose, adequate monitoring should be recommended.Keywords
This publication has 40 references indexed in Scilit:
- Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepinBiochemical Pharmacology, 2007
- Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domainActa Pharmacologica Sinica, 2007
- Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656Journal of Applied Toxicology, 2007
- Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed HERG currents in Xenopus oocytesActa Pharmacologica Sinica, 2007
- Should the Use of Selective Serotonin Reuptake Inhibitors in Child and Adolescent Depression Be Banned?Psychotherapy and Psychosomatics, 2006
- Mianserin and Ventricular Tachycardia: Case Report and Review of the LiteratureCardiology, 2006
- Genetic susceptibility to acquired long QT syndrome: Pharmacologic challenge in first-degree relativesHeart Rhythm, 2005
- Effects of Irbesartan on Cloned Potassium Channels Involved in Human Cardiac RepolarizationThe Journal of pharmacology and experimental therapeutics, 2003
- Imipramine, mianserine and maprotiline block delayed rectifier potassium current in ventricular myocytesPharmacological Research, 2002
- Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine aloneActa Psychiatrica Scandinavica, 2001